What Does Elevated Troponin Mean in COVID-19?

Allan Jaffe

Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

New Approaches to the Treatment of IgA Nephropathy

Leicester IgA Nephropathy

J. Barratt

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

Cancer Before Solid Organ Transplant

Fred Hutchinson Cancer Center

C. Blosser

EADV 2024 Insights: Calciphylaxis

EADV 2024 Insights

C. Erfurt-Berge

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

Cardio-Renal Syndrome Management: What Are the Key Factors That Impa…

Patricia Kao

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

IgA Nephropathy Highlights from ASN Kidney Week 2024

ASN Kidney Week 2024 Highlights

P. Canetta

Interview with IgA Nephropathy Patient Alistair

Leicester IgA Nephropathy

L. Iga Nephropathy

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

A New Paradigm: Rethinking Hypherphosphatemia Management

Icahn School of Medicine at Mount Sinai

D. Spiegel